Protalix BioTherapeutics, Inc.

8-K Shareholder vote results Jun 25, 2026 8-K Regulation FD disclosure May 21, 2026 10-Q Quarter ended 2026-03-31 May 13, 2026 8-K Results of operations (earnings release) May 13, 2026 10-K Fiscal year ended 2025-12-31 Mar 18, 2026 8-K Results of operations (earnings release) Mar 18, 2026 8-K Other events Mar 9, 2026 8-K Regulation FD disclosure Feb 11, 2026 8-K Other events Jan 30, 2026 8-K Regulation FD disclosure Jan 5, 2026 10-Q Quarter ended 2025-09-30 Nov 13, 2025 8-K Results of operations (earnings release) Nov 13, 2025 8-K Other events Nov 3, 2025 8-K Regulation FD disclosure; Other events Oct 17, 2025 8-K Entered a material agreement Aug 22, 2025 10-Q Quarter ended 2025-06-30 Aug 14, 2025 8-K Results of operations (earnings release) Aug 14, 2025 8-K Other events Aug 1, 2025 8-K Entered a material agreement; Director or officer change Jul 21, 2025 8-K Shareholder vote results Jun 26, 2025 10-Q Quarter ended 2025-03-31 May 9, 2025 8-K Results of operations (earnings release) May 9, 2025 8-K Director or officer change Apr 23, 2025 8-K Entered a material agreement; Other events Mar 17, 2025 10-K Fiscal year ended 2024-12-31 Mar 17, 2025 8-K Results of operations (earnings release) Mar 17, 2025 8-K Modified rights of security holders; Amended charter or bylaws Dec 31, 2024 8-K Regulation FD disclosure Dec 23, 2024 10-Q Quarter ended 2024-09-30 Nov 14, 2024 8-K Results of operations (earnings release) Nov 14, 2024 8-K Regulation FD disclosure Oct 25, 2024 10-Q Quarter ended 2024-06-30 Aug 14, 2024 8-K Results of operations (earnings release) Aug 14, 2024 8-K Shareholder vote results Jun 28, 2024 10-Q Quarter ended 2024-03-31 May 10, 2024 8-K Results of operations (earnings release) May 10, 2024 10-K Fiscal year ended 2023-12-31 Mar 14, 2024 8-K Results of operations (earnings release) Mar 14, 2024 8-K Regulation FD disclosure Dec 26, 2023 10-Q Quarter ended 2023-09-30 Nov 6, 2023